Treatment and prognosis of mature (non‐anaplastic) T‐ and NK‐cell lymphomas in childhood, adolescents, and young adults

Abstract

Paediatric non-Hodgkin lymphomas (pNHL) are a diverse group of malignancies characterised by nodal and/or extranodal involvement. Less common pNHL forms include those derived from mature T-and natural killer (NK) cells. Much of our current understanding of paediatric mature (non-anaplastic) T/NK-cell lymphomas with respect to pathogenesis, diagnosis and treatment is extrapolated from adult literature. At the Sixth International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma, convened September 26-29, 2018 in Rotterdam, The Netherlands, some important aspects on diagnosis and outcomes of mature (non-anaplastic) T/NK-cell lymphoma in children and adolescents were discussed and will be reviewed in here.

Durable Response in Relapsed Adolescent Peripheral T-cell Lymphoma: A Case Report and Review of the Literature

“…These are both histone deacetylase inhibitors with encouraging results from clinical trials; however, in a single-institutional study of 4 pediatric patients with multiple relapsed/refractory PTCL, romidepsin was unsuccesful. 20,21 There are numerous other agents that are still under investigation in clinical or preclinical trials to determine their utility in PTCL. Nivolumab, the anti-PD1 antibody FDA approved for the treatment of relapsed and refractory Hodgkin's lymphoma, shows potential after a phase I study reported objective response rate of 40% in adults with PTCL.…”

“…Romidepsin and belinostat are also both FDA approved for relapsed and refractory PTCL in the adult population. These are both histone deacetylase inhibitors with encouraging results from clinical trials; however, in a single-institutional study of 4 pediatric patients with multiple relapsed/refractory PTCL, romidepsin was unsuccesful 20,21…”